Matching hallmarks of cancer complexity with N-of-1 precision oncology.

Recent hallmarks of cancer iterations1 posit that durable control requires mechanism-guided co-targeting of hallmark capabilities rather than single-pathway inhibition. Translating this systems-level precision oncology framework at scale remains challenging. Sicklick et al.2 show that N-of-1, molecularly matched multi-drug regimens are feasible without traditional phase 1 trials; survival scales linearly with matching score, not number of drugs or dose.